This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 5mg | $70 | 3-6 Days |
| 10mg | $100 | 3-6 Days |
| 25mg | $150 | 3-6 Days |
| 50mg | $245 | 3-6 Days |
| 100mg | $445 | 3-6 Days |
| 250mg | $880 | 3-6 Days |
| 500mg | $1450 | 3-6 Days |
: Cat #: V2094 CAS #: 1284150-65-7 Purity ≥ 98%
Description: Azeliragon 2HCl (formerly TTP-488 dihydrochloride; PF04494700) is an orally bioactive RAGE (Receptor for Advanced Glycation End products) inhibitor that has the potential for the treatment of mild-to-moderate AD/Alzheimer's disease and cerebral amyloid angiopathy. RAGE is a pattern recognition receptor that affects the movement of amyloid (a biomarker for Alzheimer's disease) into the brain. In preclinical studies, azeliragon decreased brain amyloid in mice and improved their performance on behavior tests. Azeliragon has been shown to be involved in adaptive immune responses. It is currently in Phase 3 clinical trial.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 605.14 |
|---|---|
| Molecular Formula | C32H40Cl3N3O2 |
| CAS No. | 1284150-65-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 10 mM |
| Water: <1 mg/mL | |
| Ethanol: N/A | |
| SMILES Code | CCN(CC)CCCOC1=CC=C(C2=CN(C3=CC=C(OC4=CC=C(Cl)C=C4)C=C3)C(CCCC)=N2)C=C1.[H]Cl.[H]Cl |
| Synonyms | PF-04494700 2HCl; PF 04494700 2HCl; PF04494700 2HCl; Azeliragon 2HCl; TTP488 2HCl; TTP-488 2HCl; TTP 488 2HCl; PF-04494700 diHCl; PF 04494700 diHCl; PF04494700 diHCl; Azeliragon diHCl; TTP488 diHCl; TTP-488 diHCl; TTP 488 diHCl; TTP488 dihydrochloride; TTP-488 dihydrochloride; TTP 488 dihydrochloride; PF-04494700 dihydrochloride; PF 04494700 dihydrochloride; PF04494700 dihydrochloride; Azeliragon dihydrochloride |
| Protocol | In Vitro | In vitro activity: Azeliragon (also known as TTP488 and PF-04494700) is a potent and orally bioactive RAGE (Receptor for Advanced Glycation End products) inhibitor that has the potential for the treatment of mild-to-moderate Alzheimer's disease and cerebral amyloid angiopathy. RAGE is a pattern recognition receptor that affects the movement of amyloid (a biomarker for Alzheimer's disease) into the brain. In preclinical studies, azeliragon decreased brain amyloid in mice and improved their performance on behavior tests. Azeliragon has been shown to be involved in adaptive immune responses. It is currently in Phase 3 clinical trial. Cell Assay: Azeliragon is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of Azeliragon in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices. |
|---|---|---|
| In Vivo | Azeliragon is administered i.p. daily at a dose of 100 mcg/d. Successful use of the RAGE inhibitor Azeliragon in Phase II testing has led to a Phase III clinical trial for AD patients. | |
| Animal model | NA |
| Related Biological Data |
|
|---|
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 1.6525 mL | 8.2626 mL | 16.5251 mL | 33.0502 mL |
| 5mM | 0.3305 mL | 1.6525 mL | 3.3050 mL | 6.6100 mL |
| 10mM | 0.1653 mL | 0.8263 mL | 1.6525 mL | 3.3050 mL |
| 20mM | 0.0826 mL | 0.4131 mL | 0.8263 mL | 1.6525 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.